Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoinflammatory & Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADA2 drug discovery, covering wild-type and disease mutants, gene delivery, benchmark antibodies, and pathway partners.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADA2 Recombinant Protein (WT & Disease Mutants G357R, R169C, M334V). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View ADA2 Products |
| Gene Delivery | ADA2 Lentivirus / Promise-ORF. Full-length ORF for stable secretion and cell-based assays. | View ADA2 Products |
| Benchmark Ab | Anti-ADA2 Recombinant Antibody. Sequence-defined positive control for binding and neutralization. | View ADA2 Products |
| Validator | ADA2 siRNA Set. For knockdown verification and specificity controls in cellular models. | View ADA2 Products |
| Isoform Control | ADA1 Recombinant Protein. Counter-screening ortholog; adenosine deaminase isoform with distinct tissue distribution. | View ADA1 Products |
| Pathway Partner A | ADORA2A Recombinant Protein. Downstream adenosine receptor for pathway interaction studies. | View ADORA2A Products |
| Pathway Partner B | CD73 (NT5E) Recombinant Protein. Synergistic adenosinergic node; critical for combination therapy screening. | View CD73 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Glycosylation & Homodimerization | HEK293 Expressed (Native Glycosylation) to preserve natural homodimer conformation. |
| Isoform Selectivity (ADA1 vs ADA2) | Purified ADA1 and ADA2 proteins with distinct enzymatic signatures; >95% purity; Sequence Verified. |
| Disease Variant Functional Validation | Mutant Panel (G357R, R169C, M334V) for DADA2 mechanism studies; High Purity; Theoretical MW confirmed. |
| Enzymatic Activity Standardization | Active enzyme format with validated adenosine-to-inosine conversion capacity; Endotoxin <1 EU/µg. |
| Lack of Cellular Controls | ADA2 Lentivirus and predesigned siRNA for overexpression and knockdown specificity checks. |
| Immunogenicity Risk Assessment | Endotoxin-controlled antigen for ADA monitoring; Human/Mouse/Cyno orthologs available for cross-reactivity pre-screening. |
Live ADA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADA2 (Adenosine Deaminase 2) therapeutics is intensifying, driven by the need to treat DADA2 (Deficiency of ADA2) and the target's emerging role in the Tumor Microenvironment (TME). The landscape is bifurcating between rare disease enzyme replacement/gene therapy and broader immunology/oncology applications.
Rare Disease (DADA2): Early interventions relied on TNF inhibitors to manage autoinflammatory symptoms. The next wave targets curative Enzyme Replacement Therapy (ERT) and gene therapy. Key players include Ultragenyx, Spark/Roche, and Freeline, advancing subcutaneous ERT formulations and AAV-based one-time cures. As genomic screening increases DADA2 diagnosis, demand for replacement therapies is accelerating.
Immuno-Oncology & Inflammation: ADA2 regulates extracellular adenosine—a potent immunosuppressor. Modulating ADA2 is being explored to overcome resistance in solid tumor immunotherapy, with interest from Incyte, AstraZeneca, Takeda, and Biogen. Small molecule inhibitors targeting isoform-selective inhibition (ADA2 vs ADA1) are under development, along with monoclonal antibodies for TME remodeling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement Therapy (ERT) | Ultragenyx, Spark/Roche, Academic Biotechs | DADA2 (Vasculitis, Autoinflammatory) | High-concentration stability & glycosylation pattern analysis (Need HEK293-expressed native protein) |
| Gene Therapy (AAV/Lentivirus) | Freeline, Academic Consortia | Monogenic Vasculitis (DADA2) | Immunogenicity assays (Need Endotoxin-controlled antigen for ADA monitoring) |
| Small Molecule Inhibitors | Takeda, Biogen | Inflammatory Disease (RA, SLE), Solid Tumors | Isoform Selectivity Panel (Need purified ADA1 vs ADA2 with enzymatic activity) |
| Monoclonal Antibodies / IO Modulators | Incyte, AstraZeneca, Preclinical Biotechs | Solid Tumors (TME Remodeling) | Binding & inhibition assay, Adenosine pathway integration (Need ADORA2A co-reagents) |
Key Assay Challenges Addressed by TarMart
- Native Conformation: HEK293 expression ensures correct glycosylation and homodimer formation, critical for enzyme activity and reduced immunogenicity.
- Disease Variants: Recombinant mutant proteins (G357R, R169C, M334V) enable function loss studies and ERT efficacy validation.
- Selectivity Screening: Pairing ADA2 with ADA1 and species orthologs (human/mouse/cyno) allows robust counter-screening in inhibitor development.
- Endotoxin Control: Low endotoxin (<1 EU/µg) levels support in vivo PK/PD and immunogenicity studies.
- Complete Toolbox: From antigen to lentivirus to siRNA to antibodies, enabling seamless workflow from target validation to lead optimization.